Skip to content
DataLookout
Start free
Menu

NCT07870889

Vortosiran in Atrial Fibrillation

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Primary objective
Timeframe: At week 16
Primary endpoint
Timeframe: At week 16

Secondary (1)

Secondary objective

Arms and interventions

Low dose group receiving vortosiran.Active comparator

The low-dose group will receive two doses of vortosiran, the first dose at Day X and the second at Day Y. After 24 weeks, the participants will start an open-label part of the trial and receive apixaban until the end of the trial.

High dose group receiving vortosiran.Active comparator

The low-dose group will receive two doses of vortosiran, the first dose at Day X and the second at Day Y. After 24 weeks, the participants will start an open-label part of the trial and receive apixaban until the end of the trial.

Group receiving apixabanActive comparator

The third treatment group will receive apixaban during the entire trial.

Drugs: Vortosiran, Apixaban

Sites

15 sites in 4 countries

Poland 8, Sweden 3, Denmark 2, Norway 2